Literature DB >> 25680837

Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study.

Ragnar Nesvåg1, Gun Peggy Knudsen, Inger Johanne Bakken, Anne Høye, Eivind Ystrom, Pål Surén, Anne Reneflot, Camilla Stoltenberg, Ted Reichborn-Kjennerud.   

Abstract

PURPOSE: To compare the prevalence and pattern of comorbid substance use disorders (SUD) between patients with schizophrenia, bipolar disorder, and depressive illness.
METHODS: Data on presence of alcohol use disorder (AUD) and non-alcohol drug use disorder (DUD) were retrieved from the Norwegian Patient Register for individuals born between 1950 and 1989 who in the period 2009-2013 were diagnosed with schizophrenia, bipolar disorder or depressive illness according to the 10th version of the WHO International Classification of Diseases. The prevalence of AUD only, DUD only, or both was compared between men and women across age and diagnostic groups.
RESULTS: The prevalence of SUD was 25.1 % in schizophrenia (AUD: 4.6 %, DUD: 15.6 %, AUD and DUD: 4.9 %), 20.1 % in bipolar disorder (AUD: 8.1 %, DUD: 7.6 %, AUD and DUD: 4.4 %), and 10.9 % in depressive illness (AUD: 4.4 %, DUD: 4.3 %, AUD and DUD: 2.2 %). Middle-aged men with bipolar disorder had the highest prevalence of AUD (19.1 %) and young men with schizophrenia had the highest prevalence of DUD (29.6 %). Of the specific DUDs, all but sedative use disorder were more prevalent in schizophrenia than the other groups. Cannabis and stimulant use disorder was found among 8.8 and 8.9 %, respectively, of the men with schizophrenia.
CONCLUSIONS: The alarmingly high prevalence of DUD among young patients with severe mental disorders should encourage preventive efforts to reduce illicit drug use in the adolescent population.

Entities:  

Mesh:

Year:  2015        PMID: 25680837     DOI: 10.1007/s00127-015-1025-2

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.328


  37 in total

1.  The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Howard Birnbaum; Olga Demler; Ian R H Falloon; Elizabeth Gagnon; Margaret Guyer; Mary J Howes; Kenneth S Kendler; Lizheng Shi; Ellen Walters; Eric Q Wu
Journal:  Biol Psychiatry       Date:  2005-07-14       Impact factor: 13.382

2.  Mental illness in a rural area: a Norwegian psychiatric epidemiological study.

Authors:  Einar Kringlen; Svenn Torgersen; Victoria Cramer
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-05-26       Impact factor: 4.328

Review 3.  A neurobiological basis for substance abuse comorbidity in schizophrenia.

Authors:  R A Chambers; J H Krystal; D W Self
Journal:  Biol Psychiatry       Date:  2001-07-15       Impact factor: 13.382

4.  Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis.

Authors:  Johanna Koskinen; Johanna Löhönen; Hannu Koponen; Matti Isohanni; Jouko Miettunen
Journal:  Schizophr Bull       Date:  2009-04-22       Impact factor: 9.306

Review 5.  Clinical aspects of substance abuse in persons with schizophrenia.

Authors:  Juan C Negrete
Journal:  Can J Psychiatry       Date:  2003-02       Impact factor: 4.356

6.  Young cases of schizophrenia identified in a national inpatient register--are the diagnoses valid?

Authors:  Ch Dalman; J Broms; J Cullberg; P Allebeck
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2002-11       Impact factor: 4.328

7.  Impact of persistent substance misuse on 1-year outcome in first-episode psychosis.

Authors:  Aidan Turkington; Ciaran C Mulholland; Teresa M Rushe; Rick Anderson; Rosalind McCaul; Suzanne L Barrett; Ruth S Barr; Stephen J Cooper
Journal:  Br J Psychiatry       Date:  2009-09       Impact factor: 9.319

8.  Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences.

Authors:  Howard C Margolese; Leslie Malchy; Juan Carlos Negrete; Raymond Tempier; Kathryn Gill
Journal:  Schizophr Res       Date:  2004-04-01       Impact factor: 4.939

9.  Diagnosing comorbidity in psychiatric hospital: challenging the validity of administrative registers.

Authors:  Terje Oiesvold; Mary Nivison; Vidje Hansen; Ingunn Skre; Line Ostensen; Knut W Sørgaard
Journal:  BMC Psychiatry       Date:  2013-01-08       Impact factor: 3.630

10.  Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.

Authors:  Marta Di Forti; Hannah Sallis; Fabio Allegri; Antonella Trotta; Laura Ferraro; Simona A Stilo; Arianna Marconi; Caterina La Cascia; Tiago Reis Marques; Carmine Pariante; Paola Dazzan; Valeria Mondelli; Alessandra Paparelli; Anna Kolliakou; Diana Prata; Fiona Gaughran; Anthony S David; Craig Morgan; Daniel Stahl; Mizanur Khondoker; James H MacCabe; Robin M Murray
Journal:  Schizophr Bull       Date:  2013-12-17       Impact factor: 9.306

View more
  24 in total

Review 1.  Bipolar Depression and Cognitive Impairment: Shared Mechanisms and New Treatment Avenues.

Authors:  Colin A Depp; Sheena Dev; Lisa T Eyler
Journal:  Psychiatr Clin North Am       Date:  2015-12-11

2.  Impact of substance use disorder on gray matter volume in schizophrenia.

Authors:  Margaret Quinn; Maureen McHugo; Kristan Armstrong; Neil Woodward; Jennifer Blackford; Stephan Heckers
Journal:  Psychiatry Res Neuroimaging       Date:  2018-08-03       Impact factor: 2.376

3.  Prevalence, Employment Rate, and Cost of Schizophrenia in a High-Income Welfare Society: A Population-Based Study Using Comprehensive Health and Welfare Registers.

Authors:  Stig Evensen; Torbjørn Wisløff; June Ullevoldsæter Lystad; Helen Bull; Torill Ueland; Erik Falkum
Journal:  Schizophr Bull       Date:  2015-10-03       Impact factor: 9.306

4.  Performance in Practice: Practice Assessment Tool for the Care of Patients With Schizophrenia.

Authors:  Laura J Fochtmann; Jennifer Medicus; Seung-Hee Hong
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

5.  Can a rapid measure of self-exposure to drugs of abuse provide dimensional information on depression comorbidity?

Authors:  Eduardo Roque Butelman; Silvia Bacciardi; Angelo Giovanni Icro Maremmani; Maya Darst-Campbell; Joel Correa da Rosa; Mary Jeanne Kreek
Journal:  Am J Addict       Date:  2017-06-27

6.  Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis.

Authors:  Ashley M Schnakenberg Martin; Kelsey A Bonfils; Beshaun J Davis; Elizabeth A Smith; Kelly Schuder; Paul H Lysaker
Journal:  Schizophr Res Cogn       Date:  2016-10-10

7.  Perils of Pragmatic Psychiatry: How We Can Do Better.

Authors:  Maju Mathew Koola; Joseph Sebastian
Journal:  HSOA J Psychiatry Depress Anxiety       Date:  2016-02-23

8.  Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study.

Authors:  Nanna Gilliam Toftdahl; Merete Nordentoft; Carsten Hjorthøj
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-08-11       Impact factor: 4.328

9.  Differential Effect of Community Rehabilitation Reform on Hospitalizations of Patients with Chronic Psychotic Disorders With and Without Substance Use Disorder, Israel, 1991-2016.

Authors:  S Florentin; Y Neumark; S Raskin; T Bdolah-Abram; P Rosca
Journal:  Adm Policy Ment Health       Date:  2021-03

10.  Prevalence and Demographic Correlates of Substance Use among Adults with Mental Illness in Eastern Cape, South Africa: A Cross-Sectional Study.

Authors:  Linda Tindimwebwa; Anthony Idowu Ajayi; Oladele Vincent Adeniyi
Journal:  Int J Environ Res Public Health       Date:  2021-05-19       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.